Invest in intelligence that delivers

Newest Oral DMTs Haven’t Yet Made a Big Impact in the MS World

From: MDedge Neurology

By: Bruce Jancin


The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in…

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:


Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.